BioNTech SE
BNTX
$96.37
-$0.36-0.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.53B | 3.13B | 2.97B | 2.98B | 3.30B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.53B | 3.13B | 2.97B | 2.98B | 3.30B |
| Cost of Revenue | 607.84M | 631.14M | 608.79M | 584.76M | 518.02M |
| Gross Profit | 2.92B | 2.49B | 2.36B | 2.39B | 2.78B |
| SG&A Expenses | 597.28M | 589.12M | 631.01M | 648.05M | 660.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 769.66M | 341.02M | 652.17M | 698.51M | 193.20M |
| Total Operating Expenses | 4.42B | 3.95B | 4.33B | 4.37B | 3.78B |
| Operating Income | -885.53M | -823.97M | -1.36B | -1.39B | -475.90M |
| Income Before Tax | -575.80M | -430.21M | -840.49M | -731.97M | -339.05M |
| Income Tax Expenses | 57.46M | -48.29M | -27.86M | -14.84M | 161.73M |
| Earnings from Continuing Operations | -633.26 | -381.92 | -812.62 | -717.13 | -500.78 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -633.26M | -381.92M | -812.62M | -717.13M | -500.78M |
| EBIT | -885.53M | -823.97M | -1.36B | -1.39B | -475.90M |
| EBITDA | -509.70M | -544.53M | -1.09B | -1.12B | -295.63M |
| EPS Basic | -2.63 | -1.58 | -3.38 | -2.99 | -2.08 |
| Normalized Basic EPS | -1.22 | -0.78 | -1.86 | -1.58 | -0.60 |
| EPS Diluted | -2.63 | -1.60 | -3.40 | -3.00 | -2.11 |
| Normalized Diluted EPS | -1.22 | -0.78 | -1.86 | -1.59 | -0.62 |
| Average Basic Shares Outstanding | 961.42M | 963.84M | 962.63M | 962.81M | 962.27M |
| Average Diluted Shares Outstanding | 961.42M | 966.82M | 965.61M | 965.80M | 966.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |